AbbVie Inc (ABBV) – AbbVie showing progress in its pipeline by approval of SKYRIZI

in , on June 19, 2019

AbbVie’s revenues declined by 1.3% to $7.83bn in Q1FY19 and increased by 0.4% operationally. The revenues declined due to a decrease in HUMIRA international revenues due to the biosimilar competition. However, HUMIRA revenues from the U.S. increased by 7.1% to $3.2bn in Q1FY19 and will not face biosimilar competition in the U.S. until FY23.

Number of Pages – 42

Contents

Executive Summary

Financial Statements

–Income Statement and Forecast

–Balance Sheet

–Cash Flow

–Q1FY19 – Overview

–Q1FY19 – Product Revenue

–Q1FY19 – R&D Update

–FY19 Guidance

–Conclusion

–GAAP to Non-GAAP reconciliation

Historical Performance

–Key Ratios

–Profitability Ratios, Asset Turnover Ratio, Growth Ratio

–Per Share Items and Key Ratios

–Key Balance Sheet and Cash Flow ratios

–P/E Band

Product Performance and Key Developments

–Ownership

–Competition

–Key Developments

Valuation and Consensus Performance

–Relative Valuation

–Analyst Recommendations

Market Price Performance

CrispIdea Coverage Chart

Release Information

  • Released
    :

    June 19, 2019

  • Last Updated
    :

    June 27, 2019